Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TK1 | P04183 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | TK2 | O00142 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311498 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL20131193 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL12111185 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL19944089 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL1311495 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL24043569 | 1.00 | LMNA (0.60) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL15491233 | 0.91 | TK1 (0.55) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL15066132 | 0.91 | TK1 (0.57) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL18873431 | 0.91 | TK1 (0.57) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL17283457 | 0.91 | TK1 (0.57) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345915-B1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20190233461-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-2558478-B1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20160355540-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20150376223-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20110275794-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011130289-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355540-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | TYMP, NT5C3B, DUT | LMNA 2399/4885SMN1; SMN2 1370/4885TK1 57/4885 |
| US-20150376223-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | TYMP, NT5C3B, DUT | LMNA 2399/4885SMN1; SMN2 1370/4885TK1 57/4885 |
| US-20190233461-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | TYMP, NT5C3B, DUT | LMNA 2399/4885SMN1; SMN2 1370/4885TK1 57/4885 |
| US-20110275794-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | TYMP, NT5C3B, DUT | LMNA 2399/4885SMN1; SMN2 1370/4885TK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.